Aridis Pharmaceuticals (ARDS) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrends ARDS vs. SCPS, AMPE, STAB, CMRA, GNCA, EFTR, ONCSQ, ATNFW, LBPSW, and AEHAWShould you be buying Aridis Pharmaceuticals stock or one of its competitors? The main competitors of Aridis Pharmaceuticals include Scopus BioPharma (SCPS), Ampio Pharmaceuticals (AMPE), Statera Biopharma (STAB), Comera Life Sciences (CMRA), Genocea Biosciences (GNCA), eFFECTOR Therapeutics (EFTR), OncoSec Medical (ONCSQ), 180 Life Sciences (ATNFW), 4D pharma (LBPSW), and Aesther Healthcare Acquisition (AEHAW). These companies are all part of the "pharmaceutical products" industry. Aridis Pharmaceuticals vs. Scopus BioPharma Ampio Pharmaceuticals Statera Biopharma Comera Life Sciences Genocea Biosciences eFFECTOR Therapeutics OncoSec Medical 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Scopus BioPharma (NASDAQ:SCPS) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, community ranking, dividends, analyst recommendations, earnings, profitability and institutional ownership. Which has stronger valuation and earnings, SCPS or ARDS? Scopus BioPharma has higher earnings, but lower revenue than Aridis Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioScopus BioPharmaN/AN/A-$11.61MN/AN/AAridis Pharmaceuticals$3.09M0.00-$30.37M-$0.16N/A Which has more volatility & risk, SCPS or ARDS? Scopus BioPharma has a beta of -0.11, suggesting that its share price is 111% less volatile than the S&P 500. Comparatively, Aridis Pharmaceuticals has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Do institutionals & insiders believe in SCPS or ARDS? 9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. 5.1% of Scopus BioPharma shares are owned by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community believe in SCPS or ARDS? Aridis Pharmaceuticals received 120 more outperform votes than Scopus BioPharma when rated by MarketBeat users. However, 100.00% of users gave Scopus BioPharma an outperform vote while only 61.00% of users gave Aridis Pharmaceuticals an outperform vote. CompanyUnderperformOutperformScopus BioPharmaOutperform Votes2100.00% Underperform VotesNo VotesAridis PharmaceuticalsOutperform Votes12261.00% Underperform Votes7839.00% Is SCPS or ARDS more profitable? Company Net Margins Return on Equity Return on Assets Scopus BioPharmaN/A N/A N/A Aridis Pharmaceuticals N/A N/A N/A Does the media prefer SCPS or ARDS? In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score. Company Overall Sentiment Scopus BioPharma Neutral Aridis Pharmaceuticals Neutral SummaryAridis Pharmaceuticals beats Scopus BioPharma on 5 of the 7 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Get Aridis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARDS vs. The Competition Export to ExcelMetricAridis PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5,000.00$6.44B$5.05B$8.82BDividend YieldN/A8.11%5.17%4.07%P/E RatioN/A10.61125.0817.74Price / SalesN/A243.751,182.0574.25Price / CashN/A22.1633.7232.53Price / BookN/A5.474.684.68Net Income-$30.37M$153.61M$119.45M$226.08M Aridis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARDSAridis PharmaceuticalsN/AN/AN/AN/A$5,000.00$3.09M0.0030SCPSScopus BioPharmaN/A$0.00flatN/A-99.3%$13,000.00N/A0.009AMPEAmpio PharmaceuticalsN/A$0.01+∞N/A-99.9%$11,000.00N/A0.0020Gap DownSTABStatera BiopharmaN/AN/AN/AN/A$10,000.00$1.49M0.0020CMRAComera Life SciencesN/A$0.00flatN/A-99.3%$9,000.00$630,000.000.002GNCAGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.91M0.0070Analyst ForecastEFTReFFECTOR Therapeutics1.308 of 5 stars$0.00flat$24.00+11,999,900.0%-100.0%$1,000.00$3.55M0.0010Negative NewsONCSQOncoSec MedicalN/AN/AN/AN/A$1,000.00N/A0.0040ATNFW180 Life SciencesN/A$0.01flatN/A-24.2%$0.00N/A0.007LBPSW4D pharmaN/AN/AN/AN/A$0.00$522,000.000.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.04-20.6%N/A-2.6%$0.00N/A0.002 Related Companies and Tools Related Companies SCPS Alternatives AMPE Alternatives STAB Alternatives CMRA Alternatives GNCA Alternatives EFTR Alternatives ONCSQ Alternatives ATNFW Alternatives LBPSW Alternatives AEHAW Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ARDS) was last updated on 11/20/2024 by MarketBeat.com Staff From Our PartnersTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands...Angel Publishing | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | SponsoredFinancial Prophecy The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe smart-money is buying this US$1 lithium stockLithium is getting white-hot once again! And that means well-timed investors who position now in the best n...Resource Stock Digest | Sponsored31 Billionaires Are Loading Up on This SectorWhy are 31 of the world's richest billionaires, like Warren Buffett, Jeff Bezos, the Walton family, and Bill G...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aridis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aridis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ARDS with Qtrade Free ARDS Stock Alerts